There are 2789 resources available
154P - Five-year follow-up of the phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in patients with HER2 positive early or locally advanced breast cancer
Presenter: Xavier Pivot
Session: ePoster Display
155P - The addition of pyrotinib in early or locally advanced HER2-positive breast cancer patients with no response to two cycles of neoadjuvant therapy: A prospective, multicenter study
Presenter: zhi gang YU
Session: ePoster Display
776P - SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, for pretreated advanced cervical cancer: Data from a clinical expansion cohort of a phase I study
Presenter: Jifeng Feng
Session: ePoster Display
777P - A prospective, single-arm, open-label study of camrelizumab, apatinib and nab-paclitaxel in patients with advanced cervical cancer
Presenter: guiling Li
Session: ePoster Display
778P - BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer
Presenter: Giorgio Bogani
Session: ePoster Display
779P - Metronomic low-dose capecitabine in metastatic, recurrent or persistent carcinoma of cervix as 3rd line and beyond
Presenter: Irappa Madabhavi
Session: ePoster Display
781P - Efficacy and safety of apatinib combined with chemotherapy in patients of cervical cancer with pulmonary metastasis
Presenter: Shuai Feng
Session: ePoster Display
849P - Demographics of Langerhans cell histiocytosis patients who died during the 2010-2017
Presenter: Sai Giridhar Gundepalli
Session: ePoster Display